Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil.

Abstract

The VIPoma syndrome is rare. It is usually caused by a neuroendocrine tumor located in the pancreas. Somatostatin analogs and interferon-a can be helpful in the symptomatic control of the disease, but the efficacy of chemotherapy in metastatic disease is limited. We report the case of a 32-yr-old patient who had a primary intestinal VIPoma with peritoneal carcinomatosis and hepatic metastases. Somatostatin analogs and conventional chemotherapy regimens were not effective on VIPoma syndrome and tumor progression. The combination of 5- fluorouracil and interferon-alpha was associated with a major clinical improvement and tumor regression. Further investigations should evaluate the place of such a combination as a first line treatment for patients with metastatic neuroendocrine tumors.

• Authors: C Cellier, C Yaghi, E Cuillerier, N Siauve, A Berger, F Carnot, C Haddad, J P Barbier, B Landi
• Journal: The American journal of gastroenterology (Am J Gastroenterol) Vol. 95 Issue 1 Pg. 289-93 (Jan 2000) ISSN: 0002-9270 [Print] United States
• PMID: 10638600 (Publication Type: Case Reports, Journal Article)

Chemical References

• Interferon-alpha
• Fluorouracil

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Fluorouracil (administration & dosage)
• Humans
• Interferon-alpha (administration & dosage)
• Jejunal Neoplasms (pathology)
• Liver Neoplasms (diagnostic imaging, drug therapy, secondary)
• Male
• Peritoneal Neoplasms (diagnostic imaging, drug therapy, secondary)
• Tomography, X-Ray Computed
• Vipoma (diagnostic imaging, drug therapy, secondary)